Kairos Pharma, LTD.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

KAPA

organization

SIC: 2834

SEC Insider

$10K

15 transactions

Summary

Kairos Pharma, LTD. (KAPA) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $10KSales: —7 insiders

Date	Insider	Type	Value
2024-11-20	Yu John S(CEO and Chairman)	Buy	$6K
2024-11-22	Samuelson Doug(Chief Financial Officer)	Buy	$4K
2024-11-25	Murali Ramachandran(VP of Research and Development)	Buy	$318
2025-10-08	Yu John S(CEO and Chairman)	A	$0
2025-10-08	Samuelson Doug(Chief Financial Officer)	A	$0
2025-10-08	Singhvi Rahul	A	$0
2025-10-08	Keyoung Hansoo Michael	A	$0
2025-10-08	Murali Ramachandran(VP of Research and Development)	A	$0
2025-10-08	Bae Hyun W.	A	$0
2025-10-08	Bhowmick Neil(Chief Scientific Officer)	A	$0
2025-09-16	Keyoung Hansoo Michael	A	$0
2025-09-16	Bae Hyun W.	A	$0
2025-01-01	Yu John S(CEO and Chairman)	A	$0
2025-01-01	Murali Ramachandran(VP of Research and Development)	A	$0
2025-01-01	Bhowmick Neil(Chief Scientific Officer)	A	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Kairos Pharma, LTD. — Contributions, Lobbying & Contracts | Poliscope